Us Congress House Bill HB2295

Us Congress 2023-2024 Regular Session

• Introduced: 3/29/23
• Refer: 3/29/23
• Refer: 4/7/23

Caption

To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, Department of Health and Human Services, Food and Drug Administration, for fiscal year 2024.

Impact

The implementation of HB 2295 will directly influence the FDA's operational budget, potentially affecting its capacity to carry out regulatory activities, oversee food safety, approve pharmaceuticals, and conduct critical public health initiatives. By constraining the financial resources available, the bill could lead to reduced efficacy in the FDA's ability to respond to emerging health issues and manage various programs that safeguard the health of the public. The funding limitation is intended to impose financial discipline, but it raises concerns about the agency's resourcefulness in effectively performing its duties.

Summary

House Bill 2295 was introduced to establish a limitation on the availability of funds for the Food and Drug Administration (FDA) under the Department of Health and Human Services for the fiscal year 2024. The bill specifies that the total amount appropriated for the FDA may not exceed $5,584,965,000. This funding cap reflects the legislative intent to control expenditure levels within federal health agencies while continuing to provide necessary services and oversight regarding public health and safety standards.

Contention

The limitations set forth in HB 2295 explore a balance between fiscal responsibility and adequate funding for health services. Critics argue that such budget constraints could undermine the health infrastructure, particularly in responding to urgent health threats and managing routine safety checks on food and drugs. Proponents, however, may contend that the bill is necessary for ensuring government accountability in spending, suggesting that agencies should operate within tighter budget frameworks while seeking efficiency and effectiveness.

Notable points

Although the bill is relatively straightforward in its funding limitation approach, it has ignited discussions concerning the broader implications for public health in the state. Stakeholders from various sectors, including healthcare advocates and public safety representatives, might express diverse opinions on the potential impact of such a funding cutback, emphasizing the critical role of the FDA in protecting citizens' health and the necessity for adequate funding to perform its mandated responsibilities.